The liposome drug delivery sector focuses on developing innovative systems that enhance the targeted delivery of medications into the body. This industry primarily includes biotechnology firms and pharmaceutical manufacturers that design and produce lipid-based formulations, such as liposomes, for various therapies including oncology and vaccines. As the demand for more effective, safer drug delivery systems rises, companies are increasingly investing in advanced technologies that optimize bioavailability and minimize side effects. The trend highlights a shift towards more personalized medicine approaches, where tailoring drug delivery to individual patient needs is becoming the norm.


The listed companies reflect a range of sizes and specializations within the liposome drug delivery industry. Ranging from startups like Genevant Sciences, founded in 2018, to larger entities like Avanti Polar Lipids, established in 1969, these companies are headquartered in various countries including Spain, Austria, and the United States. With expertise in lipid formulations, these organizations contribute to advancements in drug delivery across therapeutic areas, showcasing a commitment to innovation and quality.


Continue reading to explore the top liposome drug delivery companies.


Top 26 Liposome Drug Delivery Companies


1. Nanovex Biotechnologies


Nanovex Biotechnologies is a biotechnology company based in Honduras, founded in 2014. With a team of 23 employees, the company specializes in drug delivery systems and nanotechnology solutions. They offer a range of products, including liposomes and synthetic exosomes, aimed at improving drug efficacy and safety. Their innovative approaches are designed to address common challenges in drug delivery, such as low efficacy, toxicity, and poor bioavailability. Nanovex serves both the pharmaceutical and cosmetic industries, showcasing their versatility in applying liposome technology. The company has received funding through grants, which supports their ongoing research and development efforts in this specialized field.


2. Polymun Scientific Immunbiologische Forschung GmbH

  • Website: polymun.com
  • Ownership type: Private
  • Headquarters: Klosterneuburg, Lower Austria, Austria
  • Employee distribution: Austria 100%
  • Founded year: 1992
  • Headcount: 51-200
  • LinkedIn: polymun-scientific

Polymun Scientific Immunbiologische Forschung GmbH, founded in 1992 and based in Klosterneuburg, Austria, is a private biopharmaceutical company that specializes in the development and manufacturing of biopharmaceuticals and liposomal formulations. With a workforce of around 51-200 employees, Polymun provides comprehensive services that include process development, GMP production, and analytical method development. They primarily cater to pharmaceutical companies and research organizations seeking innovative drug delivery solutions. Polymun's expertise in liposomal technology is evident in their commitment to enhancing drug efficacy and minimizing side effects through advanced liposomal formulations. Their ongoing R&D projects, such as those involving liposomal superoxide dismutase, highlight their active role in the industry and their focus on improving therapeutic outcomes through liposomal drug delivery systems.


3. InnoMedica Holding AG

  • Website: innomedica.com
  • Ownership type: Venture Capital
  • Headquarters: Bern, Bern, Switzerland
  • Employee distribution: Switzerland 96%, Germany 4%
  • Latest funding: $16.2M, November 2021
  • Founded year: 2000
  • Headcount: 51-200
  • LinkedIn: innomedica-ag

InnoMedica Holding AG, based in Bern, Switzerland, is a pharmaceutical company founded in 2000. Initially established as a financial entity, it transitioned into a fully operational pharmaceutical firm in 2013, focusing on innovative drug delivery systems through nanocarrier technology. The company is dedicated to developing targeted therapies primarily for oncology and neurology, addressing significant medical needs with the potential for reduced side effects. InnoMedica's product pipeline includes TLD-1, aimed at improving the delivery of Doxorubicin for cancer treatment, and TLN-1, which targets neurodegenerative diseases like Parkinson's. The company has invested in a state-of-the-art GMP manufacturing facility, known as the Nanofactory, which supports their research and development efforts. InnoMedica has also secured funding, with a reported amount of approximately 16.2 million Swiss Francs in late 2021, further bolstering its capabilities in the liposomal drug delivery space.


4. Avanti Polar Lipids

  • Website: avantilipids.com
  • Ownership type: Corporate
  • Headquarters: Alabaster, Alabama, United States (USA)
  • Latest funding: $185.0M, July 2020
  • Founded year: 1969
  • Headcount: 201-500
  • LinkedIn: avanti-polar-lipids-inc-

Avanti Polar Lipids, rebranded as Avanti Research, is a life sciences company based in Alabaster, Alabama. Founded in 1969, the company specializes in high-purity lipids and lipid research tools. They provide critical services such as cGMP manufacturing and custom synthesis, catering to researchers in the pharmaceutical and biotechnology sectors. Avanti's focus on drug delivery systems and lipidomics supports advancements in therapeutic development. Their product offerings include lipids for liposome formation, cationic liposomes for transfection, and various lipid-based formulations. In 2020, Avanti was acquired by Croda International Plc, enhancing their capabilities in lipid delivery systems and expanding their reach in the pharmaceutical market. The company has received significant funding, amounting to $185 million in 2020, which underscores their growth potential and commitment to innovation in lipid research.


5. GP-Pharm

  • Website: gp-pharm.com
  • Ownership type: Private
  • Headquarters: L'Hospitalet De Llobregat, Catalonia, Spain
  • Employee distribution: Spain 53%, Argentina 45%, Uruguay 3%
  • Founded year: 2000
  • Headcount: 51-200
  • LinkedIn: lab.-gp-pharm

GP-Pharm is a private pharmaceutical company based in L'Hospitalet De Llobregat, Catalonia, Spain, founded in 2000. The company specializes in the development and manufacturing of injectable drugs, with a particular emphasis on innovative drug delivery systems. GP-Pharm has significant expertise in liposomes, microencapsulation, and lipid nanoparticles, which are essential for creating effective long-acting formulations. Their primary therapeutic areas include oncology, urology, and women's health. GP-Pharm operates a vertically integrated model, managing the entire drug development process from research and development to market entry, including preclinical and clinical studies. They also provide contract development and manufacturing services (CDMO) to other pharmaceutical companies, leveraging their advanced facilities that meet international regulatory standards. The company has established strategic partnerships to expand its market presence globally, showcasing its commitment to innovation and collaboration in the pharmaceutical sector.


6. Genevant Sciences

  • Website: genevant.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 96%, United States (USA) 4%
  • Founded year: 2018
  • Headcount: 11-50
  • LinkedIn: genevant

Genevant Sciences Corporation, founded in 2018 and based in Vancouver, British Columbia, is a biotechnology firm that specializes in nucleic acid delivery technologies. The company focuses on developing lipid nanoparticles (LNPs) to enhance the delivery of mRNA and siRNA therapies. With a robust patent estate that includes over 700 patents worldwide, Genevant has established itself as a significant player in the field of nucleic acid drug delivery. Their technology has been validated through numerous clinical programs, and they have collaborated with various pharmaceutical companies to advance innovative therapies. Genevant's expertise in lipid chemistry and formulation development allows them to address the challenges associated with delivering nucleic acid payloads effectively, making them a valuable partner in the biotechnology sector.


7. Exelead

  • Website: exeleadbiopharma.com
  • Ownership type: Corporate
  • Headquarters: Indianapolis, Indiana, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: $780.0M, January 2022
  • Founded year: 2017
  • Headcount: 201-500
  • LinkedIn: exelead

Exelead is a pharmaceutical manufacturer based in Indianapolis, Indiana, founded in 2017. The company specializes in contract manufacturing services, focusing on lipid nanoparticles, liposomes, and pegylation formulations. Exelead supports pharmaceutical and biotech companies by guiding them through the complexities of drug development and production. Their services range from preclinical development to commercial manufacturing, ensuring that clients can navigate the entire process effectively. With a workforce of around 75 employees, Exelead has established itself as a capable partner for both emerging and established pharmaceutical companies. In January 2022, Exelead secured significant funding of $780 million, which underscores investor confidence in their business model and growth potential. The company has also been recognized for its expertise in liposomal formulation, making it a relevant player in the biopharmaceutical industry.


8. NovoArc GmbH

  • Website: novoarc.at
  • Ownership type: Private
  • Headquarters: Vienna, Vienna, Austria
  • Employee distribution: Austria 100%
  • Founded year: 2021
  • Headcount: 1-10
  • LinkedIn: novoarc

NovoArc GmbH, founded in 2021 and based in Vienna, Austria, is a private pharmaceutical company dedicated to the development and manufacturing of specialized lipids for drug formulation. With a small team of around 15 employees, NovoArc focuses on creating tetraether lipids that enhance the stability and efficacy of active pharmaceutical ingredients. Their products cater primarily to pharmaceutical companies looking for advanced solutions in drug delivery, particularly in oral and parenteral applications. NovoArc operates under stringent quality standards and has developed a patented biotechnological process for lipid production, ensuring high quality and scalability. Their innovative lipids are designed to withstand harsh conditions, making them suitable for various applications, including the delivery of small molecules, proteins, and nucleic acids. The company has also formed an advisory board comprising experts from academia and industry, further solidifying its position in the pharmaceutical landscape.


9. Micropore Technologies Ltd

  • Website: microporetech.com
  • Ownership type: Private
  • Headquarters: Redcar, England, United Kingdom (UK)
  • Employee distribution: United Kingdom (UK) 76%, India 12%, United States (USA) 12%
  • Founded year: 2003
  • Headcount: 11-50
  • LinkedIn: micropore-technologies-ltd

Micropore Technologies Ltd, founded in 2003 and based in Redcar, England, is a private biotechnology firm that specializes in drug delivery systems and formulation engineering. The company focuses on providing innovative solutions for pharmaceutical companies and research institutions, particularly in the areas of lipid nanoparticles and liposomes. Their unique membrane-based technology allows for seamless scaling from laboratory discovery to commercial manufacturing, addressing the critical challenges in drug formulation. Micropore's services are designed to enhance the efficiency and effectiveness of drug delivery systems, making them a valuable partner in the pharmaceutical industry. They have a global presence, with a significant portion of their workforce located in the UK, and they are actively expanding their market reach, as evidenced by their recent appointment of a distributor in Korea. Micropore Technologies is committed to advancing drug delivery technologies and supporting clients throughout their product development journey.


10. Phosphorex

  • Website: phosphorex.com
  • Ownership type: Private Equity
  • Headquarters: Hopkinton, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: August 2024
  • Founded year: 2005
  • Headcount: 11-50
  • LinkedIn: phosphorexllc

Phosphorex, founded in 2005 and based in Hopkinton, Massachusetts, is a contract development and manufacturing organization (CDMO) that specializes in innovative drug delivery solutions tailored for the pharmaceutical and biotechnology sectors. With a team of 18 dedicated professionals, Phosphorex focuses on particle-based formulations, particularly lipid nanoparticles and liposomes, which are essential for effective drug delivery. Their services range from formulation feasibility and optimization to process development and pre-clinical batch manufacturing. Phosphorex is committed to supporting clients through the complexities of drug development, ensuring that their advanced delivery systems meet the specific needs of therapeutic products. The company has completed numerous projects and served a variety of clients, showcasing their expertise in the field. They are also preparing to offer cGMP manufacturing capabilities in 2024, further enhancing their service offerings in the drug delivery space.


11. Precision NanoSystems is now part of Cytiva


Precision NanoSystems, now integrated into Cytiva, is a biotechnology firm based in Vancouver, British Columbia. Founded in 2010, the company specializes in lipid nanoparticle technologies that are pivotal for genomic medicines, particularly mRNA vaccines and therapeutics. They offer a range of services from formulation development to cGMP manufacturing, primarily catering to biopharmaceutical companies engaged in drug development across various diseases. Their innovative NanoAssemblr technology facilitates the efficient production of lipid nanoparticles, which are essential for effective drug delivery. Precision NanoSystems has established itself as a key player in the biopharma sector, supporting the advancement of therapies for oncology, rare diseases, and infectious diseases. Their expertise in lipid-based delivery systems, including liposomes, underscores their relevance in the drug delivery landscape.


12. ForDoz Pharma Corp

  • Website: fordozpharma.com
  • Ownership type: Private
  • Headquarters: East Windsor, New Jersey, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 2014
  • Headcount: 11-50
  • LinkedIn: fordoz-pharma-corp

ForDoz Pharma Corp, based in East Windsor, New Jersey, is a private pharmaceutical company founded in 2014. The firm specializes in the development, manufacturing, and commercialization of complex injectable products, particularly focusing on addressing significant unmet medical needs for patients suffering from severe and chronic diseases. Recently, ForDoz received FDA approval for its first liposomal product, Doxorubicin Hydrochloride Liposome Injection, which was launched in the U.S. market in August 2024. This product highlights their expertise in liposome technology. The company operates a state-of-the-art cGMP sterile manufacturing facility, which is crucial for producing high-quality injectable products. In addition to their proprietary products, ForDoz also offers Contract Development and Manufacturing Organization (CDMO) services, assisting other pharmaceutical companies in developing and manufacturing complex injectables. Their internal R&D capabilities and experienced team further enhance their position in the pharmaceutical industry.


13. DIVERSA Technologies


DIVERSA Technologies, founded in 2022 and based in Santiago De Compostela, A Coruña, Spain, is a biotechnology company focused on advancing drug delivery systems. The company specializes in creating innovative nanoparticle formulations tailored for a variety of therapeutic molecules. Their primary clientele includes researchers and pharmaceutical companies, indicating a strong presence in the biotech sector. DIVERSA's technology aims to address significant challenges in drug development by overcoming biological barriers, thereby enhancing the efficiency of new therapies. They offer a range of products, including lipid nanoparticles for mRNA, proteins, peptides, and small molecules, which are essential for effective drug delivery. The company operates with a small team, emphasizing agility and specialized expertise in their field.


14. Lifecare Innovations Private Limited


Lifecare Innovations Private Limited, founded in 2000 and based in New Delhi, India, is a biotechnology firm that focuses on liposomal technology and controlled release pharmaceuticals. The company is dedicated to developing and manufacturing innovative healthcare products aimed at treating serious fungal infections, particularly for immunocompromised patients. Their notable products include FUNGISOME® Gel and FUNGISOME® i.v., which are designed to enhance the efficacy and safety of Amphotericin B, a well-known antifungal agent. Lifecare Innovations has made significant strides in the field of liposomal drug delivery, being recognized for its pioneering work in this area. The company has received multiple awards for its contributions to biotechnology and has established a reputation for innovation in liposomal formulations. Lifecare Innovations operates with a strong emphasis on research and development, continually seeking to improve its product offerings and address critical healthcare challenges.


15. Thermosome

  • Website: thermosome.com
  • Ownership type: Venture Capital
  • Headquarters: Planegg, Bavaria, Germany
  • Employee distribution: Germany 100%
  • Latest funding: Seed, $2.2M, April 2016
  • Founded year: 2015
  • Headcount: 11-50
  • LinkedIn: thermosome

Thermosome is a biotechnology firm based in Planegg, Bavaria, Germany, founded in 2015. The company is dedicated to developing targeted tumor therapies and immune stimulation strategies for cancer treatment. Their innovative approach centers around thermosensitive liposomes (TSLs), which utilize a novel phospholipid to encapsulate anticancer drugs. This technology allows for a significant increase in local drug concentrations at the tumor site, enhancing treatment efficacy while minimizing systemic toxicity. Thermosome's lead product, THE001, is currently in a Phase I clinical trial, aimed at treating locally advanced soft tissue sarcoma. The company has received seed funding of approximately €2.17 million, which supports its research and development efforts in the pharmaceutical sector. With a small team of 11-50 employees, Thermosome is positioned to make impactful contributions to cancer therapy through its innovative drug delivery systems.


16. TTY Biopharm Company Limited


TTY Biopharm Company Limited, founded in 1960 and based in Taipei, Taiwan, is a private pharmaceutical and biotech firm that specializes in the development and manufacturing of innovative drug formulations. The company primarily focuses on oncology and anti-infection therapies, aiming to improve patient outcomes through advanced biopharmaceuticals and branded generic drugs. TTY has made significant strides in the field of liposome technology, with a dedicated pipeline for liposomal products, including Lipo-Dox, a liposomal injection that has received recognition for its quality and innovation. The company operates under stringent manufacturing standards, ensuring compliance with international regulations, which enhances its credibility in the global market. TTY's strategic initiatives include collaborations with international biotech firms, positioning itself as a key player in the development of high-barrier formulations and biopharmaceuticals. With a workforce of around 500 employees, TTY continues to expand its reach in both domestic and international markets, focusing on the development of critical drugs and healthcare products.


17. NAL Pharma/IA Capital


NAL Pharma, established in 2006 and based in Hong Kong, is a private biopharmaceutical company dedicated to advancing drug delivery systems and novel dosage forms. The company collaborates with pharmaceutical firms to enhance drug delivery and improve patient compliance across various therapeutic areas, including oncology, pain management, and central nervous system disorders. NAL Pharma's proprietary technologies, such as Bio-NN, leverage liposome encapsulation to prolong the bio half-life of drugs, thereby improving their efficacy and reducing toxicity. The company actively seeks partnerships for the development and commercialization of its products, which include innovative formulations for both existing and new drug entities. NAL Pharma operates internationally, with a focus on expediting product development and market entry through collaborations with global pharmaceutical partners.


18. OZ Biosciences

  • Website: ozbiosciences.com
  • Ownership type: Private
  • Headquarters: Marseille, Provence-Alpes-Côte D'Azur, France
  • Employee distribution: France 74%, United States (USA) 26%
  • Latest funding: July 2003
  • Founded year: 2003
  • Headcount: 11-50
  • LinkedIn: oz-biosciences

OZ Biosciences, founded in 2003 and based in Marseille, France, is a biotechnology firm that specializes in advanced molecular delivery systems. The company provides a variety of products, including transfection reagents, viral applications, and notably, lipid nanoparticles (LNPs). These LNPs are essential for the delivery of mRNA and other therapeutic agents, making them a critical component in modern drug delivery strategies. OZ Biosciences serves a clientele that includes researchers and pharmaceutical companies, highlighting their commitment to supporting the biotechnology and life sciences sectors. The company operates primarily in France and the United States, with a workforce of around 19 employees. Their innovative approaches, such as the NanOZ-LNP technology, demonstrate their active involvement in the development of effective drug delivery solutions.


19. Aspire Pharmaceuticals

  • Website: aspire-pharma.com
  • Ownership type: Corporate
  • Headquarters: United Kingdom (UK)
  • Employee distribution: United States (USA) 100%
  • Latest funding: June 2015
  • Founded year: 2009
  • Headcount: 51-200
  • LinkedIn: aspire-pharmaceuticals

Aspire Pharmaceuticals, founded in 2009 and based in the United Kingdom, is a pharmaceutical manufacturer that specializes in encapsulation solutions tailored for the nutritional supplement and over-the-counter (OTC) markets. With a workforce of around 83 employees, the company operates as a contract development-manufacturing organization (CDMO), providing services that span from product innovation to manufacturing and packaging. Aspire is particularly noted for its expertise in softgel and liquid capsule development, and it has recently expanded its offerings to include liposomal systems. This focus on liposomal technology aims to improve the bioavailability of active ingredients, addressing a significant challenge in both the nutraceutical and pharmaceutical industries. Their client base includes a variety of businesses, from startups to established consumer packaged goods (CPG) companies, all seeking effective delivery systems to enhance product efficacy and consumer compliance.


20. Marama Labs

  • Website: maramalabs.com
  • Ownership type: Venture Capital
  • Headquarters: Dublin, Dublin, Ireland
  • Employee distribution: New Zealand 88%, Ireland 12%
  • Latest funding: Seed, $2.1M, December 2024
  • Founded year: 2017
  • Headcount: 11-50
  • LinkedIn: marama-labs

Marama Labs is a biotechnology company based in Dublin, Ireland, founded in 2017. The firm focuses on advanced analytical technology aimed at improving drug formulation processes. Their flagship product, CloudSpec™, is a patented solution that allows for rapid and accurate quantification of RNA in lipid nanoparticles, addressing a critical need in the pharmaceutical and biotechnology sectors. This technology is particularly valuable for researchers and developers working with liposomes and other nanoparticle formulations, as it overcomes traditional measurement challenges associated with light scattering. Marama Labs has recently secured funding of approximately €2.07 million to support its operations, indicating investor confidence in its innovative capabilities and potential impact on drug delivery analysis.


21. Acuitas Therapeutics

  • Website: acuitastx.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 100%
  • Founded year: 2009
  • Headcount: 51-200
  • LinkedIn: acuitastx

Acuitas Therapeutics, founded in 2009 and based in Vancouver, British Columbia, is a biotechnology company that specializes in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. The company collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to advance innovative therapies aimed at addressing unmet clinical needs. Acuitas is recognized for its clinically validated LNP technology, which has been instrumental in the development of Onpattro™, an RNAi therapeutic approved for treating transthyretin amyloidosis. Additionally, Acuitas has played a pivotal role in the development of the COVID-19 vaccine COMIRNATY®, in partnership with BioNTech and Pfizer. Their extensive intellectual property portfolio and commitment to advancing nucleic acid medicines underscore their significant contributions to the field of drug delivery.


22. BBB Therapeutics

  • Website: bbbtherapeutics.com
  • Ownership type: Private
  • Headquarters: Leiden, South Holland, Netherlands
  • Founded year: 2003
  • Headcount: 11-50
  • LinkedIn: to-bbb

BBB Therapeutics, also known as 2-BBB Medicines B.V., is a biotechnology company based in Leiden, Netherlands. Founded in 2003, the company emerged from the Blood-Brain Barrier Research Group at Leiden University. It specializes in developing innovative drug delivery systems aimed at treating brain and eye diseases. The company’s proprietary G-Technology® is a CNS-targeted liposome formulation that enhances the delivery of pharmaceuticals across the blood-brain barrier and blood-retina barrier. This technology is pivotal in addressing significant medical needs in oncology and neuro-inflammation. BBB Therapeutics has established partnerships with other firms to advance its lead programs, which include treatments for brain cancer and hereditary retinal degeneration. Their focus on liposomal formulations positions them as a relevant player in the drug delivery industry, particularly for CNS applications.


23. Lipomize

  • Website: lipomize.com
  • Ownership type: Private
  • Headquarters: Argentina
  • Employee distribution: Argentina 100%
  • Founded year: 2011
  • Headcount: 1-10
  • LinkedIn: lipomize

Lipomize SRL, based in Argentina, is a private company founded in 2011 that specializes in the development and manufacturing of liposomal formulations. They cater to the pharmaceutical, dermocosmetic, and nutraceutical industries, providing innovative solutions aimed at enhancing the efficacy of active ingredients. With a small team of around 25 employees, Lipomize focuses on high-quality standards and has established itself as a regional player with a global presence. Their services include product development, technology transfer, and external consultancy, particularly in the area of lipid nanoparticles and liposomes. They are certified with ISO 9001 and ISO 22716, ensuring adherence to strict quality protocols. Lipomize exports to various countries, including the USA, Spain, and India, indicating their international reach and commitment to expanding their market presence.


24. Bioserv Corporation

  • Website: bioservamerica.com
  • Ownership type: Corporate
  • Headquarters: San Diego, California, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: July 2007
  • Founded year: 1988
  • Headcount: 11-50
  • LinkedIn: bioserv-corporation

Bioserv Corporation, founded in 1988 and based in San Diego, California, operates as a contract manufacturing organization (CMO) specializing in pharmaceutical and biotechnology services. The company offers a range of services, including aseptic and non-aseptic fill and finish, custom manufacturing, and compliance with FDA regulations. Bioserv caters primarily to clients in the pharmaceutical and medical device sectors, providing high-quality manufacturing solutions for clinical trials and product development. Notably, they have capabilities in producing lipid-based vehicles and liposomes, which are critical components in drug delivery systems. Their facilities are equipped to handle complex formulations, and they have a strong focus on quality and compliance, ensuring that their processes meet stringent regulatory standards. Bioserv has manufactured numerous products for studies across multiple countries, showcasing their operational capacity and commitment to supporting the pharmaceutical industry.


25. PlantaCorp GmbH

  • Website: plantacorp.com
  • Ownership type: Private
  • Headquarters: Hamburg, Hamburg, Germany
  • Employee distribution: Germany 97%, United Kingdom (UK) 3%
  • Founded year: 2011
  • Headcount: 51-200
  • LinkedIn: plantacorp

PlantaCorp GmbH, founded in 2011 and based in Hamburg, Germany, is a private company that specializes in the manufacturing of nutritional supplements with a focus on liposomal formulations. The company operates with a team of approximately 51-200 employees and has established itself as a provider of both white label and custom liposomal supplements. Their products are designed to enhance bioavailability, allowing for better nutrient absorption, which is a critical factor in the health and wellness sector. PlantaCorp emphasizes scientific research and development, conducting bioavailability studies to validate the effectiveness of their liposomal products. They cater primarily to businesses looking for high-quality supplement solutions, positioning themselves as a reliable partner in the nutritional supplement market. Their commitment to sustainability is also notable, as they utilize green energy in their production processes.


26. Celon Laboratories Limited

  • Website: celonlabs.com
  • Ownership type: Corporate
  • Headquarters: Hyderabad, Telangana, India
  • Employee distribution: India 100%
  • Latest funding: November 2020
  • Founded year: 2007
  • Headcount: 501-1000
  • LinkedIn: celon-laboratories-limited

Celon Laboratories Limited, based in Hyderabad, Telangana, India, is a biopharmaceutical company founded in 2007. The company specializes in oncology and critical care formulations, aiming to improve patient outcomes through high-quality medications. Celon develops and manufactures a wide range of products, including innovative treatments for cancer and critical care, which are essential in hospital and healthcare settings. Their product offerings include notable liposomal formulations, such as Liposomal Amphotericin B, which highlights their expertise in novel drug delivery systems. Celon adheres to global quality standards and has established a robust presence in over 46 markets worldwide, with more than 650 product registrations. The company is committed to making medicines more accessible and continues to expand its portfolio to meet the evolving needs of healthcare providers.



Liposome Drug Delivery Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
Nanovex BiotechnologiesHonduras11-502014Private
Polymun Scientific Immunbiologische Forschung GmbHKlosterneuburg, Lower Austria, Austria51-2001992Private
InnoMedica Holding AGBern, Bern, Switzerland51-2002000Venture Capital
Avanti Polar LipidsAlabaster, Alabama, United States (USA)201-5001969Corporate
GP-PharmL'Hospitalet De Llobregat, Catalonia, Spain51-2002000Private
Genevant SciencesVancouver, British Columbia, Canada11-502018Private
ExeleadIndianapolis, Indiana, United States (USA)201-5002017Corporate
NovoArc GmbHVienna, Vienna, Austria1-102021Private
Micropore Technologies LtdRedcar, England, United Kingdom (UK)11-502003Private
PhosphorexHopkinton, Massachusetts, United States (USA)11-502005Private Equity
Precision NanoSystems is now part of CytivaVancouver, British Columbia, Canada51-2002010Corporate
ForDoz Pharma CorpEast Windsor, New Jersey, United States (USA)11-502014Private
DIVERSA TechnologiesSantiago De Compostela, A Coruña, Spain1-102022Private
Lifecare Innovations Private LimitedNew Delhi, Delhi, India51-2002000Private
ThermosomePlanegg, Bavaria, Germany11-502015Venture Capital
TTY Biopharm Company LimitedTaipei, Taiwan501-10001960Private
NAL Pharma/IA CapitalHong Kong S.A.R51-2002006Private
OZ BiosciencesMarseille, Provence-Alpes-Côte D'Azur, France11-502003Private
Aspire PharmaceuticalsUnited Kingdom (UK)51-2002009Corporate
Marama LabsDublin, Dublin, Ireland11-502017Venture Capital
Acuitas TherapeuticsVancouver, British Columbia, Canada51-2002009Private
BBB TherapeuticsLeiden, South Holland, Netherlands11-502003Private
LipomizeArgentina1-102011Private
Bioserv CorporationSan Diego, California, United States (USA)11-501988Corporate
PlantaCorp GmbHHamburg, Hamburg, Germany51-2002011Private
Celon Laboratories LimitedHyderabad, Telangana, India501-10002007Corporate


Want to Find More Liposome Drug Delivery Companies?

If you want to find more companies that offer targeted therapies and innovative drug delivery solutions you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

  • Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
  • Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
  • Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!